Literature DB >> 28285690

The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation.

Toyohisa Iriki1, Koji Ohnishi2, Yukio Fujiwara2, Hasita Horlad2, Yoichi Saito2, Cheng Pan2, Koei Ikeda3, Takeshi Mori3, Makoto Suzuki3, Hidenori Ichiyasu4, Hirotsugu Kohrogi4, Motohiro Takeya2, Yoshihiro Komohara5.   

Abstract

OBJECTIVES: Small cell lung cancer (SCLC) is an aggressive tumor with a poor prognosis. It is well known that various stromal cells, including macrophages, play a role in tumor progression in several types of malignant tumors; however, the significance of tumor-associated macrophages (TAMs) in SCLC has not been fully elucidated. Signal transducer and activator of transcription 3 (STAT3) is a molecule well-known to be related to tumor progression. In the present study, we investigated the relationship of TAMs and SCLC cells to test the hypothesis that TAMs induce tumor progression in SCLC via STAT3 activation.
MATERIALS AND METHODS: We performed immunohistochemical analysis using surgically resected tumor specimens and in vitro co-culture experiments using human SCLC cell lines and human monocyte-derived macrophages.
RESULTS: We first demonstrated via immunostaining that STAT3 activation in tumor cells was predominantly observed in the peripheral areas of tumor nests existing near TAMs in stroma. The indirect co-culture of SCLC cells and macrophages induced STAT3 activation in both cell types, and macrophage-derived culture supernatant (CS) significantly activated STAT3 in SCLC cells. Macrophage-derived CS induced tumor cell proliferation and invasion via STAT3 activation. In addition, chemo-resistance and sphere formation were also increased by macrophage-derived CS. Macrophage-derived interleukin-6 and CC chemokine ligand 4 (CCL4/MIP-1β) were suggested to be associated with STAT3 activation in SCLC cells. CS-induced STAT3 activation in SCLC cells was suppressed by anti-IL-6 receptor antibody, but not by anti-CCL4/MIP-1β antibody.
CONCLUSION: These results suggest that TAMs are likely involved in SCLC progression via STAT3 activation and TAM-derived IL-6 is indicated to be one of molecules related to STAT3 activation in SCLC cells. Thus, the cell-cell interaction between TAMs and SCLC cells might be a target for therapy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Interleukin-6; Signal transducer and activator of transcription 3; Small cell lung cancer; Tumor-associated macrophage

Mesh:

Substances:

Year:  2017        PMID: 28285690     DOI: 10.1016/j.lungcan.2017.01.003

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  18 in total

1.  Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.

Authors:  Nese Unver; Oliver Delgado; Kirubel Zeleke; Amber Cumpian; Ximing Tang; Mauricio S Caetano; Hong Wang; Hiroyuki Katayama; Hua Yu; Eva Szabo; Ignacio I Wistuba; Seyed Javad Moghaddam; Samir M Hanash; Edwin J Ostrin
Journal:  Int J Cancer       Date:  2017-12-23       Impact factor: 7.396

2.  Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.

Authors:  Tara Jarboe; Neha Y Tuli; Sanjukta Chakraborty; Rachana R Maniyar; Nicole DeSouza; Augustine Moscatello; Jan Geliebter; Raj K Tiwari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors.

Authors:  Maggie Musick; Xianzhong Yu
Journal:  Immunol Res       Date:  2022-04-29       Impact factor: 4.505

4.  Thymoquinone Augments Cisplatin-Induced Apoptosis on Esophageal Carcinoma Through Mitigating the Activation of JAK2/STAT3 Pathway.

Authors:  Xue Hu; Jingjing Ma; Vikash Vikash; Jiao Li; Dandan Wu; Ya Liu; Jixiang Zhang; Weiguo Dong
Journal:  Dig Dis Sci       Date:  2017-12-02       Impact factor: 3.199

5.  Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice.

Authors:  Di Zhang; Jonathan Rennhack; Eran R Andrechek; Cheryl E Rockwell; Karen T Liby
Journal:  Antioxid Redox Signal       Date:  2018-04-16       Impact factor: 8.401

6.  IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.

Authors:  Grazia Carbotti; Amin Reza Nikpoor; Paola Vacca; Rosaria Gangemi; Chiara Giordano; Francesco Campelli; Silvano Ferrini; Marina Fabbi
Journal:  J Exp Clin Cancer Res       Date:  2017-10-11

7.  DIF-1 inhibits growth and metastasis of triple-negative breast cancer through AMPK-mediated inhibition of the mTORC1-S6K signaling pathway.

Authors:  Fumi Seto-Tetsuo; Masaki Arioka; Koichi Miura; Takeru Inoue; Kazunobu Igawa; Katsuhiko Tomooka; Fumi Takahashi-Yanaga; Toshiyuki Sasaguri
Journal:  Oncogene       Date:  2021-07-24       Impact factor: 9.867

8.  Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.

Authors:  I-Ying Kuo; You-En Yang; Pei-Shan Yang; Yu-Jou Tsai; Hong-Tai Tzeng; Hung-Chi Cheng; Wan-Ting Kuo; Wu-Chou Su; Chih-Peng Chang; Yi-Ching Wang
Journal:  Theranostics       Date:  2021-05-12       Impact factor: 11.556

9.  Transcriptional and Microenvironmental Landscape of Macrophage Transition in Cancer: A Boolean Analysis.

Authors:  Ugo Avila-Ponce de León; Aarón Vázquez-Jiménez; Meztli Matadamas-Guzman; Rosana Pelayo; Osbaldo Resendis-Antonio
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

Review 10.  The Potential Biomarkers and Immunological Effects of Tumor-Derived Exosomes in Lung Cancer.

Authors:  Shamila D Alipoor; Esmaeil Mortaz; Mohammad Varahram; Mehrnaz Movassaghi; Aletta D Kraneveld; Johan Garssen; Ian M Adcock
Journal:  Front Immunol       Date:  2018-04-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.